David Michael Hyman

David Michael Hyman

Top Cited Scholar 2025
Auto-generated profile, based on publicly available information

David Michael Hyman

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2019 in Nature
Verified
Journal Article
Closed access
PDF file
NVNeil Vasan
Neil Vasan
JBJosé Baselga
José Baselga
DHDavid M. Hyman
David M. Hyman

22 February 2018 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
ADAlexander Drilon
Alexander Drilon
TLTheodore W. Laetsch
Theodore W. Laetsch
SKShivaani Kummar
Shivaani Kummar
SDSteven G. DuBois
Steven G. DuBois
ULUlrik N. Lassen
Ulrik N. Lassen
DHDavid M. Hyman
David M. Hyman
Fusions involving one of three tropomyosin receptor kinases (TRK) occur in diverse cancers in children and adults. We evaluated the efficacy and safety of larotrectinib, a highly selective TRK inhibitor, in adults and children who had tumors with these fusions. We enrolled patients with consecutively and prospectively identified TRK fusion–positive cancers, detected by molecular profiling as routinely performed at each site, into one of three protocols: a phase 1 study involving adults, a phase 1–2 study involving children, or a phase 2 study involving adolescents and adults. The primary end point for the combined analysis was the overall response rate according to independent review. Secondary end points included duration of response, progression-free survival, and safety. A total of 55 patients, ranging in age from 4 months to 76 years, were enrolled and treated. Patients had 17 unique TRK fusion–positive tumor types. The overall response rate was 75% (95% confidence interval [CI], 61 to 85) according to independent review and 80% (95% CI, 67 to 90) according to investigator assessment. At 1 year, 71% of the responses were ongoing and 55% of the patients remained progression-free. The median duration of response and progression-free survival had not been reached. At a median follow-up of 9.4 months, 86% of the patients with a response (38 of 44 patients) were continuing treatment or had undergone surgery that was intended to be curative. Adverse events were predominantly of grade 1, and no adverse event of grade 3 or 4 that was considered by the investigators to be related to larotrectinib occurred in more than 5% of patients. No patient discontinued larotrectinib owing to drug-related adverse events. Larotrectinib had marked and durable antitumor activity in patients with TRK fusion–positive cancer, regardless of the age of the patient or of the tumor type. (Funded by Loxo Oncology and others; ClinicalTrials.gov numbers, NCT02122913, NCT02637687, and NCT02576431.)

2 February 2018 in Science
Verified
Journal Article
Closed access
PDF file
DCDiego Chowell
Diego Chowell
LMLuc Morris
Luc Morris
CGClaud M. Grigg
Claud M. Grigg
JWJeffrey K. Weber
Jeffrey K. Weber
RSRobert M Samstein
Robert M Samstein
TCTimothy A. Chan
Timothy A. Chan
HLA genotype affects response: Immunotherapy works by activating the patient's own immune system to fight cancer. For effective tumor killing, CD8 + T cells recognize tumor peptides presented by human leukocyte antigen class I (HLA-I) molecules. In humans, there are three major HLA-I genes ( HLA-A, HLA-B , and HLA-C ). Chowell et al. asked whether germline HLA-I genotype influences how T cells recognize tumor peptides and respond to checkpoint inhibitor immunotherapies (see the Perspective by Kvistborg and Yewdell). They examined more than 1500 patients and found that heterozygosity at HLA-I loci was associated with better survival than homozygosity for one or more HLA-I genes. Thus, specific HLA-I mutations could have implications for immune recognition and for the design of epitopes for cancer vaccines and immunotherapies. Science , this issue p. 582 ; see also p. 516

25 November 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
PRPedram Razavi
Pedram Razavi
BLBob T. Li
Bob T. Li
DBDavid N. Brown
David N. Brown
BJByoungsok Jung
Byoungsok Jung
EHEarl Hubbell
Earl Hubbell
Jorge S. Reis-FilhoJorge S. Reis-Filho
Jorge S. Reis-Filho

16 July 2018 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
CBCraig M. Bielski
Craig M. Bielski
AZAhmet Zehir
Ahmet Zehir
APAlexander V. Penson
Alexander V. Penson
MDMark T. A. Donoghue
Mark T. A. Donoghue
WCWalid Chatila
Walid Chatila
BTBarry S. Taylor
Barry S. Taylor

2 August 2019 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
JSJames P. Solomon
James P. Solomon
ILIrina Linkov
Irina Linkov
ARAndrea Rosado
Andrea Rosado
KMKerry Mullaney
Kerry Mullaney
EREzra Y. Rosen
Ezra Y. Rosen
JHJaclyn F. Hechtman
Jaclyn F. Hechtman